Experts Discuss Effects of Cancer on Memory and Thinking at Free Symposium
CINCINNATIThe University of Cincinnati (UC) Cancer Institute and UC Gardner Neuroscience Institute are holding a free seminar Saturday, Sept. 24, to educate patients and the community on the effect of cancer and cancer therapy on memory loss and critical thinking.
The event, which will take place from 8 a.m. to 12:15 p.m. at the Kingsgate Marriott Conference Center, 151 Goodman Drive, will involve presentations from and interactive discussions with oncology and neuroscience experts.
"There is a fog in the understanding of chemo brain and its prevention or treatment; however, lessons learned from dementia research and other neurodegenerative diseases indicate that risk factors can be identified and moderated, and brain regeneration can be stimulated and restored, says Rhonna Shatz, DO, associate professor in the Department of Neurology and Rehabilitation Medicine and director of the Memory Disorders Center, who will be speaking at the event. "We hope to share some of these insights during this event and better educate those in our community on this important topic.
Experts will speak about how cancer and its treatments affect sleep, mood disorders, like depression, and nutrition, among other quality of life factors, including how cognition may be affected in pediatric cancer survivors.
"This conference represents a great collaborative effort between the UC Gardner Neuroscience Institute and the UC Cancer Institute, and we hope to educate patients whose memory could be affected by cancer or cancer treatment, says William Barrett, MD, professor and chair of the Department of Radiation Oncology at the UC College of Medicine and director of the UC Cancer Institute.
Free continental breakfast will be provided for attendees; for more information, contact Kelly Hummel at kelly.hummel@uc.edu or 513-558-2030.
Related Stories
Cancer Center plays key role in lab research, clinical trials for new pancreatic cancer drug
September 1, 2026
WLWT and WCPO highlighted the contributions of University of Cincinnati Cancer Center researchers that helped lead to the recent FDA approval of daraxonrasib, a new treatment for pancreatic cancer.
Cancer Center physician receives $150,000 New Investigator Research Grant to study treatment-resistant leukemia
September 1, 2026
The University of Cincinnati Cancer Center’s Sarah Skuli, MD, PhD, received a two‑year, $150,000 Leukemia Research Foundation New Investigator Grant to study TP53‑mutated leukemia, a treatment‑resistant subtype with very poor outcomes.
Heavy social media use linked to depression
August 31, 2026
U.S. News and World Report, Yahoo! News, MSN, USA Today and other national media highlight a new study by the University of Cincinnati and Northwestern University that found a correlation between heavy social media use and depression in adults.